An AllTrials project

NCT05359081: An ongoing trial by Sumitomo Pharma Co., Ltd.

This trial is completed, but has been granted a delay in reporting its results. It must report results 1 year, 3 months from now.

Full data

Full entry on ClinicalTrials.gov NCT05359081
Title A 52-week, Open-label Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date May 16, 2022
Completion date March 21, 2024
Required reporting date March 21, 2027, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Dec. 12, 2025
Days late None